Baricitinib Relieves DSS-induced Ulcerative Colitis in Mice by Suppressing the NF-κB and JAK2/STAT3 Signalling Pathways

Overview

Journal Inflammopharmacology

Specialty Pharmacology

Date 2024 Jan 16

PMID 38227095

Authors

Qiong Wu

YangYang Liu

Jinmeiqi Liang

Ao Dai

Boyu Du

Xueyan Xi

Lan Jin

Yang Guo

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a relapsing inflammatory disease with a unique aetiology. The treatment of UC is challenging, and the current clinical therapeutics for colitis have limited efficacy. Thus, finding new and effective treatment options remains urgent. Baricitinib, an inhibitor of Janus kinase (JAK), has been clinically used to treat rheumatoid arthritis (RA). However, its potential effects on UC have not been fully elucidated. In this study, we aimed to explore the effects of baricitinib on UC and its underlying mechanism. Dextran sulphate sodium (DSS)-induced murine model of chronic colitis was used to investigate the intervention efficacy following oral administration of baricitinib. The levels of key cytokines, such as IL-6, IFN-γ and IL-17A, were determined. Moreover, western blotting for IκBα, p-IκBα, JAK2, p-JAK2, STAT3 and p-STAT3 protein expression was performed to investigate the associated signalling pathways. Our findings demonstrated that baricitinib can significantly relieve DSS-induced UC in mice. After baricitinib intervention, IL-6, IFN-γ and IL-17A levels were decreased both in vitro and in vivo. Moreover, the elevated expression levels of p-IκBα, p-JAK2, and p-STAT3 were significantly reduced after treatment. Collectively, these results suggest that baricitinib is a potential therapeutic agent for alleviation of DSS-induced colitis. This study provides a method for subsequent investigations on potential curative drugs development of the for colitis.

References

Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S . Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets. 2013; 14(12):1508-21. DOI: 10.2174/13894501113146660224. View

Ashwood P, Harvey R, Verjee T, Wolstencroft R, Thompson R, Powell J . Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1 in ulcerative colitis. Inflamm Res. 2004; 53(2):53-9. DOI: 10.1007/s00011-003-1219-z. View

Atreya R, Neurath M . Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005; 28(3):187-96. DOI: 10.1385/CRIAI:28:3:187. View

Barbulescu A, Askling J, Chatzidionysiou K, Forsblad-dElia H, Kastbom A, Lindstrom U . Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford). 2022; 61(10):3952-3962. PMC: 9536798. DOI: 10.1093/rheumatology/keac068. View

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

Begue B, Wajant H, Bambou J, Dubuquoy L, Siegmund D, Beaulieu J . Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology. 2006; 130(7):1962-74. DOI: 10.1053/j.gastro.2006.03.022. View

Coskun M, Salem M, Pedersen J, Nielsen O . Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013; 76:1-8. DOI: 10.1016/j.phrs.2013.06.007. View

Coward S, Clement F, Benchimol E, Bernstein C, Avina-Zubieta J, Bitton A . Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019; 156(5):1345-1353.e4. DOI: 10.1053/j.gastro.2019.01.002. View

Danese S, Grisham M, Hodge J, Telliez J . JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2015; 310(3):G155-62. PMC: 4971816. DOI: 10.1152/ajpgi.00311.2015. View

10.

Dang E, Barbi J, Yang H, Jinasena D, Yu H, Zheng Y . Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011; 146(5):772-84. PMC: 3387678. DOI: 10.1016/j.cell.2011.07.033. View

11.

Fang X, Hong Y, Dai L, Qian Y, Zhu C, Wu B . CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol Carcinog. 2017; 56(11):2434-2445. DOI: 10.1002/mc.22691. View

12.

Lohr J, Knoechel B, Wang J, Villarino A, Abbas A . Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006; 203(13):2785-91. PMC: 2118184. DOI: 10.1084/jem.20061341. View

13.

Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y . The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol. 1995; 30 Suppl 8:56-60. View

14.

Nakase H, Sato N, Mizuno N, Ikawa Y . The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2021; 21(3):103017. DOI: 10.1016/j.autrev.2021.103017. View

15.

Neurath M . Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-42. DOI: 10.1038/nri3661. View

16.

OShea J, Plenge R . JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012; 36(4):542-50. PMC: 3499974. DOI: 10.1016/j.immuni.2012.03.014. View

17.

OShea J, Holland S, Staudt L . JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013; 368(2):161-70. PMC: 7604876. DOI: 10.1056/NEJMra1202117. View

18.

Plichta D, Graham D, Subramanian S, Xavier R . Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. Cell. 2019; 178(5):1041-1056. PMC: 6778965. DOI: 10.1016/j.cell.2019.07.045. View

19.

Reimund J, Wittersheim C, Dumont S, Muller C, Baumann R, Poindron P . Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996; 16(3):144-50. DOI: 10.1007/BF01540912. View

20.

Segal J, LeBlanc J, Hart A . Ulcerative colitis: an update. Clin Med (Lond). 2021; 21(2):135-139. PMC: 8002778. DOI: 10.7861/clinmed.2021-0080. View